Takeda Pharmaceutical stock
Price history
+58.67% over the period1 year: from ¥4,372.00 (November 17, 2025) to ¥6,937.00 (November 16, 2026), +58.67%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥6,937.00 |
| October 30, 2026 | ¥6,651.00 |
| September 30, 2026 | ¥5,780.00 |
| August 31, 2026 | ¥5,765.00 |
| July 31, 2026 | ¥5,513.00 |
| June 30, 2026 | ¥5,155.00 |
| May 29, 2026 | ¥5,118.00 |
| April 30, 2026 | ¥5,270.00 |
| March 31, 2026 | ¥5,664.00 |
| February 27, 2026 | ¥5,819.00 |
| January 30, 2026 | ¥5,242.00 |
| December 30, 2025 | ¥4,835.00 |
| November 28, 2025 | ¥4,506.00 |
| November 17, 2025 | ¥4,372.00 |
At a glance
The company
Researches, develops, manufactures and markets pharmaceutical products in gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines and neuroscience
Latest results
Quarter to September 30, 2026 · EPS ¥120.88 (estimate ¥45.70)
Next event
Dividend
TickerLandia's take on Takeda Pharmaceutical
- Pricier than similar companies: trailing 12-month P/E 253 vs 41 (+515%) in a group of 11.
- Strong point: Market momentum (93/100 in its group). Weak point: Financial strength (14/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.74% from the 52-week high
Analysts · 16 analysts
Average target¥6,815.81−1.75% vs. price
Buy 11 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Takeda Pharmaceutical
Compared with similar companies: very strong momentum, very high dividend, and very low financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage51
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 253.2 99 Price/sales 2.34 36 Forward P/E 40.1 85 EV/EBITDA 11.3 26 Price/book 1.48 12 Profitabilitylow25
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 64.8% 47 Operating margin 16.6% 32 ROE 0.6% 12 Net margin 0.9% 12 ROA 3.3% 22 Earnings stabilityaverage48
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.1% 72 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 23 Growthlow22
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +6.68% 36 Earnings growth (year over year) −1,687.14% 1 Average revenue growth (3 years) +3.81% 28 Financial strengthvery low14
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 3.95 7 Interest coverage 4.10 12 Debt/equitycounts in reverse: lower means more financial strength 0.72 22 Current ratio 1.15 17 Dividendvery high88
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 3.1% 89 Consecutive dividend years 27 years 80 Payout ratiopays out more than its earnings 773.8% 95 Market momentumvery strong93
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +58.13% 89 Distance from 200-day average +23.62% 94 Relative strength (3 months) +39.93% 98 Relative strength (6 months) +38.78% 92 Riskvery low15
How much the price swings.
Metric Value Position in group Beta (1 year) −0.01 6 Maximum drawdown (12 months) 19.4% 15 Volatility (60 days) 26.9% 25
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Takeda Pharmaceutical is pricier than similar companies
Takeda Pharmaceutical's P/E (trailing 12 months): 253.2, +515% against the median of a group of 11 similar companies (41.1).
Compared with 11 similar companies
| Metric | Takeda Pharmaceutical | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 253.2 | High | |
| Forward P/E | 40.1 | Middle | |
| Operating margin | 16.6% | Low | |
| ROE | 0.6% | Low | |
| Debt/equity | 0.72 | High |
Grey band: the middle half of the group; tick: the median; dot: Takeda Pharmaceutical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥1.19T
Latest quarter · Q3 2026
Net income
¥192.43B
Latest quarter · Q3 2026
Quarterly net margin
16.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥10.48T
- P/E
- 253.2
- EPS
- ¥25.77
- Volume
- 8.02M
- Daily trading
- €182.47M
- Dividend yield
- 2.91%
How Takeda Pharmaceutical is changing
All resultsRevenue grew 7.1% a year on average over the last 5 years
Operating margin fell from 15.4% to 13.5%
Profitable in 4 of 5 fiscal years
Returns
Takeda Pharmaceutical returns with dividends
¥1,000 invested in Takeda Pharmaceutical 5 years ago, on November 16, 2021, would be worth ¥2,633 today with dividends reinvested: +163.35% in total, +21.37% per year. On price alone it would be ¥2,125 (+112.47%).
| Period | Takeda Pharmaceutical | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | +11.47% | −6.39% | ¥1,115 |
| 6 months | +31.46% | −0.42% | ¥1,315 |
| Year to date | +43.47% | +21.48% | ¥1,435 |
| 1 year | +64.32% | +21.52% | ¥1,643 |
| 3 years | +89.53% | +82.95% | ¥1,895 |
| 5 years | +163.35% | +105.15% | ¥2,633 |
| 10 years | +124.93% | +242.35% | ¥2,249 |
Over the last 6 months it has done better than 71% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
Takeda Pharmaceutical: technical analysis
Takeda Pharmaceutical is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 16.9% below its all-time closing high (¥8,350.00, June 5, 2007).
- Trend
- Upward
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +23.60%
Active signals
New 52-week high.
Support and resistance
Price areas where Takeda Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price¥6,937.00
- Support¥6,031.50−13.05%2 touches, last on September 24, 2026
- Support¥5,890.20−15.09%5 touches, last on September 3, 2026
- Support¥5,542.80−20.10%5 touches, last on October 5, 2026
Volatility and risk
Over the last year it has moved little with the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- −0.01
- Volatility (60 sessions, annualised)
- 26.5%
- Largest fall in the last year
- −19.39%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Takeda Pharmaceutical: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Takeda Pharmaceutical has been January: +1.69% on average, positive in 16 years out of 36. The weakest has been March: −0.86% on average, positive in 19 years out of 37. November, the current month, has been positive in 21 years out of 36 (+1.04% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.69% | −0.63% | 16 of 36 |
| February | −0.21% | +0.57% | 20 of 37 |
| March | −0.86% | +0.13% | 19 of 37 |
| April | +1.27% | +0.65% | 19 of 37 |
| May | −0.05% | +0.41% | 19 of 37 |
| June | −0.45% | −0.27% | 16 of 37 |
| July | +1.52% | +1.86% | 21 of 37 |
| August | −0.35% | 0.00% | 18 of 37 |
| September | +0.90% | +0.38% | 20 of 37 |
| October | +0.14% | +0.70% | 21 of 37 |
| November | +1.04% | +0.85% | 21 of 36 |
| December | +0.61% | +1.00% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Takeda Pharmaceutical and its competitors
Nearly half of the sales of this Japanese drugmaker are generated in the United States, which accounts for 48.0% of revenue, while Europe and Canada add 25.4% and Japan 9.6%. The company researches, develops, manufactures and markets pharmaceutical products, and it also out-licenses them to other companies. Its portfolio covers gastroenterology, neuroscience and oncology, with brands such as Entyvio, Adcetris, Trintellix and Vyvanse, along with the QDENGA brand.
- Headquarters
- Chuo, Japan
- Employees
- 47,029
- Founded
- 1781
- Chief executive
- Julie Kim
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Takeda Pharmaceutical4502 | $65.5B | 16.6% | 253.2 | +31.46% |
| Sun Pharmaceutical IndustriesSUNPHARMA | $47.86B | 23.3% | 41.1 | +3.02% |
| Jiangsu Hengrui Pharmaceuticals600276 | $47.82B | 27.4% | 35.9 | −11.06% |
| Divi's LaboratoriesDIVISLAB | $32.23B | 34.0% | 90.6 | +63.89% |
| Hansoh Pharmaceutical Group3692 | $26.6B | 37.3% | 28.4 | −3.58% |
| Torrent PharmaceuticalsTORNTPHARM | $18.85B | 22.2% | 78.9 | +6.48% |
Same industry or related industries, similar size. Compare Takeda Pharmaceutical with its competitors · Full profile
